CHAARTED: chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Giving six cycles of docetaxel at the start of hormone therapy for metastatic prostate cancer lengthened survival by over a year in men with high-volume disease, the first trial to show that early chemotherapy helps.
Overview
Phase 3 trial of 790 men with metastatic hormone-sensitive prostate cancer randomised to androgen deprivation alone or with six cycles of docetaxel.
Median overall survival was 57.6 versus 44.0 months (hazard ratio 0.61) overall, and 49.2 versus 32.2 months in high-volume disease; long-term follow-up showed no benefit in low-volume disease.
- Median overall survival 57.6 vs 44.0 months; hazard ratio 0.61.
- High-volume disease: 49.2 vs 32.2 months; no benefit in low-volume disease on follow-up.
Docetaxel with androgen deprivation is a standard for high-volume metastatic hormone-sensitive prostate cancer, now usually combined with an androgen receptor pathway inhibitor as triplet therapy.
- Open-label; defined the high-volume criteria (visceral metastases or four or more bone lesions with one beyond the pelvis and spine) used since.
Similar pages
not linked directly; found by shared links- Key paperLATITUDE: abiraterone plus prednisone in newly diagnosed high-risk metastatic castration-sensitive prostate cancer
Shares Metastatic hormone-sensitive prostate cancer, New England Journal of Medicine.
- Key paperARASENS: darolutamide added to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer
Shares Metastatic hormone-sensitive prostate cancer, New England Journal of Medicine.
- Key paperSTAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer
Shares Metastatic hormone-sensitive prostate cancer, New England Journal of Medicine.